Does the media refer more to TWST or MRVI?

In the previous week, Twist Bioscience had 8 more articles in the media than Maravai LifeSciences. MarketBeat recorded 20 mentions for Twist Bioscience and 12 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 0.69 beat Twist Bioscience's score of 0.64 indicating that Maravai LifeSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Twist Bioscience 4 Very Positive mention(s) 6 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maravai LifeSciences 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Do analysts recommend MRVI or STVN?

Maravai LifeSciences presently has a consensus target price of $5.83, suggesting a potential downside of 3.90%. Given Maravai LifeSciences' higher possible upside, analysts clearly believe Maravai LifeSciences is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maravai LifeSciences 2 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20 Stevanato Group 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.00

Does the media prefer MRVI or STVN?

In the previous week, Stevanato Group had 10 more articles in the media than Maravai LifeSciences. MarketBeat recorded 22 mentions for Stevanato Group and 12 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 0.69 beat Stevanato Group's score of 0.40 indicating that Maravai LifeSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maravai LifeSciences 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Stevanato Group 7 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer TXG or MRVI?

In the previous week, 10x Genomics had 5 more articles in the media than Maravai LifeSciences. MarketBeat recorded 17 mentions for 10x Genomics and 12 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 0.69 beat 10x Genomics' score of 0.60 indicating that Maravai LifeSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 10x Genomics 4 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Maravai LifeSciences 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to SHC or MRVI?

In the previous week, Sotera Health had 12 more articles in the media than Maravai LifeSciences. MarketBeat recorded 24 mentions for Sotera Health and 12 mentions for Maravai LifeSciences. Sotera Health's average media sentiment score of 0.76 beat Maravai LifeSciences' score of 0.69 indicating that Sotera Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sotera Health 9 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Maravai LifeSciences 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer MRVI or CAI?

In the previous week, Caris Life Sciences had 4 more articles in the media than Maravai LifeSciences. MarketBeat recorded 16 mentions for Caris Life Sciences and 12 mentions for Maravai LifeSciences. Caris Life Sciences' average media sentiment score of 0.80 beat Maravai LifeSciences' score of 0.69 indicating that Caris Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maravai LifeSciences 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Caris Life Sciences 7 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Maravai LifeSciences (MRVI) Competitors

$6.07 -0.16 (-2.57%)

Closing price 08/10/2026 04:00 PM Eastern

Extended Trading

$6.12 +0.05 (+0.91%)

As of 06:00 AM Eastern

Compare

MRVI vs. TWST, STVN, TXG, SHC, and CAI

Should you buy Maravai LifeSciences stock or one of its competitors? Maravai LifeSciences's main competitors and comparable companies include Twist Bioscience (TWST), Stevanato Group (STVN), 10x Genomics (TXG), Sotera Health (SHC), and Caris Life Sciences (CAI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Maravai LifeSciences compare to Twist Bioscience?

Twist Bioscience (NASDAQ:TWST) and Maravai LifeSciences (NASDAQ:MRVI) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, media sentiment, analyst recommendations and risk.

In the previous week, Twist Bioscience had 8 more articles in the media than Maravai LifeSciences. MarketBeat recorded 20 mentions for Twist Bioscience and 12 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 0.69 beat Twist Bioscience's score of 0.64 indicating that Maravai LifeSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Twist Bioscience	4 Very Positive mention(s)	6 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Maravai LifeSciences	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Twist Bioscience presently has a consensus price target of $98.30, indicating a potential downside of 21.28%. Maravai LifeSciences has a consensus price target of $5.83, indicating a potential downside of 3.90%. Given Maravai LifeSciences' higher probable upside, analysts clearly believe Maravai LifeSciences is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Twist Bioscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Twist Bioscience has higher revenue and earnings than Maravai LifeSciences. Twist Bioscience is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Twist Bioscience	$376.57M	20.80	-$77.67M	-$2.22	N/A
Maravai LifeSciences	$185.74M	8.44	-$130.77M	-$0.52	N/A

Twist Bioscience has a beta of 2.14, suggesting that its share price is 114% more volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market.

50.3% of Maravai LifeSciences shares are held by institutional investors. 3.1% of Twist Bioscience shares are held by company insiders. Comparatively, 2.5% of Maravai LifeSciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Twist Bioscience has a net margin of -31.66% compared to Maravai LifeSciences' net margin of -37.07%. Maravai LifeSciences' return on equity of -15.34% beat Twist Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Twist Bioscience	-31.66%	-28.64%	-19.94%
Maravai LifeSciences	-37.07%	-15.34%	-7.72%

Summary

Twist Bioscience beats Maravai LifeSciences on 9 of the 16 factors compared between the two stocks.

How does Maravai LifeSciences compare to Stevanato Group?

Maravai LifeSciences (NASDAQ:MRVI) and Stevanato Group (NYSE:STVN) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.

Maravai LifeSciences presently has a consensus target price of $5.83, suggesting a potential downside of 3.90%. Given Maravai LifeSciences' higher possible upside, analysts clearly believe Maravai LifeSciences is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Stevanato Group	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00

50.3% of Maravai LifeSciences shares are held by institutional investors. 2.5% of Maravai LifeSciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Stevanato Group has a net margin of 10.99% compared to Maravai LifeSciences' net margin of -37.07%. Stevanato Group's return on equity of 10.43% beat Maravai LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-37.07%	-15.34%	-7.72%
Stevanato Group	10.99%	10.43%	6.16%

In the previous week, Stevanato Group had 10 more articles in the media than Maravai LifeSciences. MarketBeat recorded 22 mentions for Stevanato Group and 12 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 0.69 beat Stevanato Group's score of 0.40 indicating that Maravai LifeSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maravai LifeSciences	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Stevanato Group	7 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Maravai LifeSciences has a beta of 0.63, indicating that its stock price is 37% less volatile than the broader market. Comparatively, Stevanato Group has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market.

Stevanato Group has higher revenue and earnings than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$185.74M	8.44	-$130.77M	-$0.52	N/A
Stevanato Group	€1.34B	4.66	€158.21M	€0.56	36.88

Summary

Stevanato Group beats Maravai LifeSciences on 11 of the 17 factors compared between the two stocks.

How does Maravai LifeSciences compare to 10x Genomics?

10x Genomics (NASDAQ:TXG) and Maravai LifeSciences (NASDAQ:MRVI) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations, profitability and media sentiment.

10x Genomics has a beta of 2.03, meaning that its stock price is 103% more volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market.

In the previous week, 10x Genomics had 5 more articles in the media than Maravai LifeSciences. MarketBeat recorded 17 mentions for 10x Genomics and 12 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 0.69 beat 10x Genomics' score of 0.60 indicating that Maravai LifeSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
10x Genomics	4 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Maravai LifeSciences	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

10x Genomics has a net margin of -12.18% compared to Maravai LifeSciences' net margin of -37.07%. 10x Genomics' return on equity of -9.41% beat Maravai LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
10x Genomics	-12.18%	-9.41%	-7.31%
Maravai LifeSciences	-37.07%	-15.34%	-7.72%

10x Genomics has higher revenue and earnings than Maravai LifeSciences. 10x Genomics is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
10x Genomics	$642.82M	11.57	-$43.54M	-$0.59	N/A
Maravai LifeSciences	$185.74M	8.44	-$130.77M	-$0.52	N/A

10x Genomics currently has a consensus target price of $36.08, suggesting a potential downside of 38.39%. Maravai LifeSciences has a consensus target price of $5.83, suggesting a potential downside of 3.90%. Given Maravai LifeSciences' higher possible upside, analysts clearly believe Maravai LifeSciences is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
10x Genomics	1 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

84.7% of 10x Genomics shares are held by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are held by institutional investors. 8.8% of 10x Genomics shares are held by company insiders. Comparatively, 2.5% of Maravai LifeSciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

10x Genomics beats Maravai LifeSciences on 11 of the 15 factors compared between the two stocks.

How does Maravai LifeSciences compare to Sotera Health?

Sotera Health (NASDAQ:SHC) and Maravai LifeSciences (NASDAQ:MRVI) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

Sotera Health has higher revenue and earnings than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sotera Health	$1.16B	4.65	$77.94M	$0.57	33.28
Maravai LifeSciences	$185.74M	8.44	-$130.77M	-$0.52	N/A

Sotera Health presently has a consensus price target of $21.50, suggesting a potential upside of 13.34%. Maravai LifeSciences has a consensus price target of $5.83, suggesting a potential downside of 3.90%. Given Sotera Health's stronger consensus rating and higher probable upside, equities analysts clearly believe Sotera Health is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sotera Health	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

91.0% of Sotera Health shares are held by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are held by institutional investors. 15.4% of Sotera Health shares are held by company insiders. Comparatively, 2.5% of Maravai LifeSciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Sotera Health had 12 more articles in the media than Maravai LifeSciences. MarketBeat recorded 24 mentions for Sotera Health and 12 mentions for Maravai LifeSciences. Sotera Health's average media sentiment score of 0.76 beat Maravai LifeSciences' score of 0.69 indicating that Sotera Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sotera Health	9 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Maravai LifeSciences	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Sotera Health has a net margin of 13.44% compared to Maravai LifeSciences' net margin of -37.07%. Sotera Health's return on equity of 40.12% beat Maravai LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sotera Health	13.44%	40.12%	7.55%
Maravai LifeSciences	-37.07%	-15.34%	-7.72%

Sotera Health has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.63, indicating that its stock price is 37% less volatile than the broader market.

Summary

Sotera Health beats Maravai LifeSciences on 15 of the 16 factors compared between the two stocks.

How does Maravai LifeSciences compare to Caris Life Sciences?

Maravai LifeSciences (NASDAQ:MRVI) and Caris Life Sciences (NASDAQ:CAI) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

Maravai LifeSciences presently has a consensus price target of $5.83, indicating a potential downside of 3.90%. Caris Life Sciences has a consensus price target of $26.33, indicating a potential upside of 12.54%. Given Caris Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Caris Life Sciences is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Caris Life Sciences	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Caris Life Sciences had 4 more articles in the media than Maravai LifeSciences. MarketBeat recorded 16 mentions for Caris Life Sciences and 12 mentions for Maravai LifeSciences. Caris Life Sciences' average media sentiment score of 0.80 beat Maravai LifeSciences' score of 0.69 indicating that Caris Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maravai LifeSciences	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Caris Life Sciences	7 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Caris Life Sciences has higher revenue and earnings than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$185.74M	8.44	-$130.77M	-$0.52	N/A
Caris Life Sciences	$348.89M	18.95	-$68.09M	$0.36	65.00

Caris Life Sciences has a net margin of 10.62% compared to Maravai LifeSciences' net margin of -37.07%. Caris Life Sciences' return on equity of 18.77% beat Maravai LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-37.07%	-15.34%	-7.72%
Caris Life Sciences	10.62%	18.77%	9.34%

Maravai LifeSciences has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market. Comparatively, Caris Life Sciences has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market.

50.3% of Maravai LifeSciences shares are owned by institutional investors. 2.5% of Maravai LifeSciences shares are owned by insiders. Comparatively, 50.0% of Caris Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Caris Life Sciences beats Maravai LifeSciences on 15 of the 16 factors compared between the two stocks.

Get Maravai LifeSciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MRVI vs. The Competition

Export

Metric	Maravai LifeSciences	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.61B	$9.56B	$7.01B	$12.98B
Dividend Yield	N/A	1.47%	2.58%	10.07%
P/E Ratio	-11.67	62.14	269.18	24.72
Price / Sales	8.44	106.69	592.48	98.19
Price / Cash	14.88	26.16	28.89	37.42
Price / Book	4.16	5.13	11.44	6.42
Net Income	-$130.77M	$56.66B	$3.45B	$347.03M
7 Day Performance	-5.60%	3.06%	1.94%	0.71%
1 Month Performance	-0.33%	0.58%	-0.55%	-0.87%
1 Year Performance	194.66%	24.39%	75.51%	21.94%

Maravai LifeSciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MRVI Maravai LifeSciences	1.7592 of 5 stars	$6.07 -2.6%	$5.83 -3.9%	+175.9%	$1.61B	$185.74M	N/A	610	Earnings Report
TWST Twist Bioscience	1.3265 of 5 stars	$100.38 -0.7%	$95.30 -5.1%	+387.1%	$6.26B	$376.57M	N/A	990	Positive News
STVN Stevanato Group	2.9469 of 5 stars	€19.52 -5.2%	N/A	-12.1%	€5.91B	€1.34B	33.07	6,010	Gap Down
TXG 10x Genomics	1.8548 of 5 stars	$46.39 -1.3%	$32.08 -30.8%	+376.6%	$5.89B	$642.82M	N/A	1,240	Earnings Report Analyst Forecast
SHC Sotera Health	3.9915 of 5 stars	$17.91 -0.5%	$20.25 +13.1%	+35.8%	$5.11B	$1.16B	43.70	3,000	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MRVI) was last updated on 8/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Maravai LifeSciences (MRVI) Competitors

MRVI vs. TWST, STVN, TXG, SHC, and CAI

How does Maravai LifeSciences compare to Twist Bioscience?

Summary

How does Maravai LifeSciences compare to Stevanato Group?

Summary

How does Maravai LifeSciences compare to 10x Genomics?

Summary

How does Maravai LifeSciences compare to Sotera Health?

Summary

How does Maravai LifeSciences compare to Caris Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRVI vs. The Competition

Maravai LifeSciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Maravai LifeSciences (MRVI) Competitors

MRVI vs. TWST, STVN, TXG, SHC, and CAI

How does Maravai LifeSciences compare to Twist Bioscience?

Does the media refer more to TWST or MRVI?

Do analysts prefer TWST or MRVI?

Which has better valuation and earnings, TWST or MRVI?

Which has more risk and volatility, TWST or MRVI?

Do insiders & institutionals believe in TWST or MRVI?

Is TWST or MRVI more profitable?

Summary

How does Maravai LifeSciences compare to Stevanato Group?

Do analysts recommend MRVI or STVN?

Do insiders & institutionals hold more shares of MRVI or STVN?

Is MRVI or STVN more profitable?

Does the media prefer MRVI or STVN?

Which has more volatility and risk, MRVI or STVN?

Which has stronger earnings and valuation, MRVI or STVN?

Summary

How does Maravai LifeSciences compare to 10x Genomics?

Which has more volatility and risk, TXG or MRVI?

Does the media prefer TXG or MRVI?

Is TXG or MRVI more profitable?

Which has better earnings and valuation, TXG or MRVI?

Do analysts recommend TXG or MRVI?

Do insiders & institutionals hold more shares of TXG or MRVI?

Summary

How does Maravai LifeSciences compare to Sotera Health?

Which has preferable earnings and valuation, SHC or MRVI?

Do analysts rate SHC or MRVI?

Do insiders & institutionals hold more shares of SHC or MRVI?

Does the media refer more to SHC or MRVI?

Is SHC or MRVI more profitable?

Which has more risk & volatility, SHC or MRVI?

Summary

How does Maravai LifeSciences compare to Caris Life Sciences?

Do analysts rate MRVI or CAI?

Does the media prefer MRVI or CAI?

Which has higher valuation and earnings, MRVI or CAI?

Is MRVI or CAI more profitable?

Which has more volatility and risk, MRVI or CAI?

Do insiders & institutionals have more ownership in MRVI or CAI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRVI vs. The Competition

Maravai LifeSciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools